Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 21 of the 22 references it cites were found in a registry or an index.

The First-in-class Anti-EGFR Antibody Mixture Sym004 Overcomes Cetuximab Resistance Mediated by EGFR Extracellular Domain Mutations in Colorectal Cancer

Open access

Published version of a preprint

Abstract

Purpose: Approved anti-EGFR antibodies cetuximab and panitumumab provide significant clinical benefit in patients with metastatic colorectal cancer (MCRC). However, patients ultimately develop disease progression, often driven by acquisition of mutations in the extracellular domain (ECD) of EGFR. Sym004 is a novel 1:1 mixture of two nonoverlapping anti-EGFR mAbs that recently showed promising clinical activity in a phase I trial in MCRC. Our aim was to determine the efficacy of Sym004 to circumvent cetuximab resistance driven by EGFR ECD mutations. Experimental Design: Functional studies were performed to assess drug–receptor binding as well as ligand-dependent activation of individual EGFR mutants in the presence of cetuximab, panitumumab, and Sym004. Cell viability and molecular effects of the drugs were assayed in cetuximab-resistant cell lines and in tumor xenograft models. Efficacy of Sym004 was evaluated in patients progressing to cetuximab that harbored EGFR mutation in the post-cetuximab tumor sample. Results: Contrary to cetuximab and panitumumab, Sym004 effectively bound and abrogated ligand-induced phosphorylation of all individual EGFR mutants. Cells resistant to cetuximab harboring mutations in EGFR maintained sensitivity to Sym004, which was consistent with an effective suppression of EGFR downstream signaling, translating into profound and sustained tumor regression in the xenograft model. As proof-of-principle, a patient with a tumor harboring an EGFR mutation (G465R) following cetuximab therapy benefited from Sym004 therapy. Conclusions: Sym004 is an active drug in MCRC resistant to cetuximab/panitumumab mediated by EGFR mutations. EGFR mutations are potential biomarkers of response to Sym004 to be evaluated in ongoing large clinical trials. Clin Cancer Res; 22(13); 3260–7. ©2016 AACR.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1158/1078-0432.ccr-15-2400

Cites

21 of 21 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 22 references

Cited by

See all 68

Metadata

Authors
Sánchez-Martín, F. J., Bellosillo, B., Gelabert-Baldrich, M., Dalmases, A., Cañadas, I., Vidal, J., Martinez, A., Argilés, G., Siravegna, G., Arena, S., Koefoed, K., Visa, L., Arpí, O., Horak, I. D., Iglesias, M., Stroh, C., Kragh, M., Rovira, A., Albanell, J., Tabernero, J., Bardelli, A., & Montagut, C.
Affiliations
  • Hospital Del Mar (ES)
  • 1Cancer Research Program, IMIM, Hospital del Mar, Barcelona, Spain.
  • Vall d'Hebron Institute of Oncology (ES)
  • Candiolo Cancer Institute (IT)
  • Symphogen (Denmark) (DK)
  • Merck Healthcare KGaA, Darmstadt (Germany) (DE)
  • Universitat Pompeu Fabra (ES)
Corresponding author
Montagut, Clara
Venue
Clinical Cancer Research
Published
2016-06-30
Volume
22
Issue
13
Pages
3260-3267
ISSN
  • 1078-0432 (ISSN-L)
  • 1557-3265
OpenAlex
W2282995421
Cited by
68
References
22
Citations by year
2026: 3 · 2025: 2 · 2024: 5 · 2023: 5 · 2022: 5 · 2021: 2 · 2020: 8 · 2019: 6 · 2018: 8 · 2017: 15 · 2016: 9
FWCI
6.82
Type
journal article
Language
en
Open access
Licence
other-oa
Locations
  • Clinical Cancer Research (publishedVersion)
  • PubMed (publishedVersion)
  • RECERCAT (Consorci de Serveis Universitaris de Catalunya) (acceptedVersion)
  • Institutional Research Information System University of Turin (University of Turin) (submittedVersion, other-oa)
  • Repositori digital de la UPF (Universitat Pompeu Fabra) (submittedVersion)
Funders
Xarxa de Banc de Tumors de Catalunya (PI12/00989, PI15/00457, DTS15/00048, RD12/0036/0051, 2014SGR740, PIE15/00008)
Topics
  • Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
  • Health Sciences › Medicine › Oncology › HER2/EGFR in Cancer Research
  • Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
Keywords
cetuximab resistance, metastatic colorectal cancer, panitumumab, EGFR phosphorylation, drug-receptor binding, tumor xenografts, treatment response biomarkers
MeSH terms
Cetuximab, Panitumumab, Animals, Antibodies, Monoclonal, Humans, Male, Mice, Inbred BALB C, Mutation, Colorectal Neoplasms, Signal Transduction, 3T3 Cells, Drug Resistance, Neoplasm, Xenograft Model Antitumor Assays, Cell Line, Tumor, Cell Proliferation, Mice, ErbB Receptors

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: The First-in-class Anti-EGFR Antibody Mixture Sym004 Overcomes Cetuximab Resistance Mediated by EGFR Extracellular Domain Mutations in Colorectal Cancer. https://app.cochat.ai/papers/10.1158/1078-0432.ccr-15-2400
The paper
Sánchez-Martín, F. J., Bellosillo, B., Gelabert-Baldrich, M., Dalmases, A., Cañadas, I., Vidal, J., Martinez, A., Argilés, G., Siravegna, G., Arena, S., Koefoed, K., Visa, L., Arpí, O., Horak, I. D., Iglesias, M., Stroh, C., Kragh, M., Rovira, A., Albanell, J., . . . Montagut, C. (2016). The First-in-class Anti-EGFR Antibody Mixture Sym004 Overcomes Cetuximab Resistance Mediated by EGFR Extracellular Domain Mutations in Colorectal Cancer. Clinical Cancer Research. https://doi.org/10.1158/1078-0432.ccr-15-2400

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.